No Data
No Data
Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $19
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Arcutis Biotherapeutics CFO Sells Shares Worth Over $110,000
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
No Data
No Data